MRI scan to check bone marrow during prostate cancer radiation therapy
Part of Cancer clinical trials.
This study tests a special MRI technique to better measure how radiation from Lu-177 PSMA therapy affects your bone marrow. The goal is to help doctors predict and manage side effects like low blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of prostate cancer (from a biopsy or tissue sample).
- Your doctor must have already decided that you should receive a standard treatment called Lu-177 PSMA therapy, which targets prostate cancer cells with radiation.
- You must be able to lie flat on your back for at least 30 minutes while having an MRI scan.
- You should not have had chemotherapy or radium-223 treatment within the past 4 weeks, and you should not be taking any medicines that stimulate or suppress your bone marrow.
- You should be generally well enough to carry out daily activities (score 0-2 on a standard scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests whether using MRI scans to guide radiation can allow lower doses to the healthy parts of the prostate, potentially reducing side effects. It is for men with intermediate- or high-risk prostate cancer that can be seen on MRI and has not spread.
This trial uses a special MRI scan (with hyperpolarized pyruvate, a naturally occurring substance) to look at prostate cancer in more detail. It aims to help doctors understand how the cancer is responding to treatment or how it might behave.
This study uses MRI scans to see how prostate cancer changes after radiation treatment, especially in the local (prostate-area) response. It may help doctors better judge treatment effectiveness and plan care more precisely.
This trial is testing how well treatments for advanced prostate cancer that has spread to the bones can be seen on scans. It may help doctors find better ways to measure if the cancer is responding to treatment.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.